Event Title
Testing of Novel Antimicrobials to Fight Antibiotic Resistance
Presentation Type
Poster/Portfolio
Presenter Major(s)
Biomedical Sciences
Mentor Information
Robert Smart, smartr@gvsu.edu
Department
Chemistry
Location
Henry Hall Atrium 67
Start Date
13-4-2011 10:00 AM
End Date
13-4-2011 11:00 AM
Keywords
Health and Wellness, Health, Illness, and Healing
Abstract
Infectious diseases continue to be internationally rampant and a leading cause of mortality even with the use of antibiotics and vaccinations. In an effort to combat emerging bacterial antibiotic resistance, we synthesize chemical compounds and test for high activity against Gram-positive bacteria, such as methicillin resistant Staphylococcus aureus (MRSA). Our leading active compounds are subjected to a minimum inhibitory concentration (MIC) test and results containing a MIC of 8ug/ml or less are then tested for minimal binding to human serum protein (HSP). We analyze our active novel compounds through IR and NMR spectroscopy in order to corroborate the structural identity. We continue to search for an antibacterial compound that preserves its minimum inhibitory concentration after being combined with human serum protein as this would be highly effective in destroying disease causing bacteria in the clinical setting.
Testing of Novel Antimicrobials to Fight Antibiotic Resistance
Henry Hall Atrium 67
Infectious diseases continue to be internationally rampant and a leading cause of mortality even with the use of antibiotics and vaccinations. In an effort to combat emerging bacterial antibiotic resistance, we synthesize chemical compounds and test for high activity against Gram-positive bacteria, such as methicillin resistant Staphylococcus aureus (MRSA). Our leading active compounds are subjected to a minimum inhibitory concentration (MIC) test and results containing a MIC of 8ug/ml or less are then tested for minimal binding to human serum protein (HSP). We analyze our active novel compounds through IR and NMR spectroscopy in order to corroborate the structural identity. We continue to search for an antibacterial compound that preserves its minimum inhibitory concentration after being combined with human serum protein as this would be highly effective in destroying disease causing bacteria in the clinical setting.